Short Interest Coverage: Aerie Pharmaceuticals Incorporated (NASDAQ:AERI) Stock Is Shorted Less

November 23, 2016 - By Richard Conner   ·   0 Comments

Short Interest Coverage: Aerie Pharmaceuticals Incorporated (NASDAQ:AERI) Stock Is Shorted Less

The stock of Aerie Pharmaceuticals Incorporated (NASDAQ:AERI) registered a decrease of 5.82% in short interest. AERI’s total short interest was 4.03M shares in November as published by FINRA. Its down 5.82% from 4.28 million shares, reported previously. With 607,300 shares average volume, it will take short sellers 7 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Incorporated’s float is 25.08%. About 94,212 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 144.06% since April 21, 2016 and is uptrending. It has outperformed by 138.73% the S&P500.

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $1.29 billion. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It currently has negative earnings. The Company’s primary product candidates are Rhopressa and Roclatan.

Insitutional Activity: The institutional sentiment increased to 2.49 in 2016 Q2. Its up 0.82, from 1.67 in 2016Q1. The ratio increased, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Blackrock Advsrs Limited Liability Corp, a Delaware-based fund reported 12,310 shares. Platinum Limited has invested 0.05% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Financial Bank Of America Corporation De has 63,546 shares for 0% of their US portfolio. Wellington Management Gp Llp has invested 0.01% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Putnam accumulated 319,900 shares or 0.01% of the stock. Tocqueville Asset Mgmt Ltd Partnership holds 42,300 shares or 0.01% of its portfolio. The California-based Wells Fargo And Mn has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Boulegeris Investments has 1.1% invested in the company for 91,770 shares. Alps Advisors holds 37,268 shares or 0.01% of its portfolio. Moreover, Vanguard Grp has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 1.01 million shares. Harvey Capital Mngmt has 0.96% invested in the company for 109,050 shares. Nationwide Fund owns 79,473 shares or 0.01% of their US portfolio. Rhumbline Advisers holds 22,960 shares or 0% of its portfolio. Northpointe Ltd Com holds 1% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 481,769 shares. Art Advsr Ltd Liability Co accumulated 36,867 shares or 0.03% of the stock.

Insider Transactions: Since July 22, 2016, the stock had 1 buying transaction, and 0 sales for $4.38 million net activity. The insider Foresite Capital Management II – LLC bought $4.38 million.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage

Out of 10 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 10 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 20 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, September 15 by Cantor Fitzgerald. RBC Capital Markets maintained it with “Outperform” rating and $50 target price in Wednesday, November 4 report. The company was maintained on Thursday, September 15 by Stifel Nicolaus. Cantor Fitzgerald reinitiated it with “Buy” rating and $44 target price in Friday, June 3 report. Cantor Fitzgerald maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Friday, August 7 with “Buy” rating. H.C. Wainwright initiated the stock with “Buy” rating in Tuesday, September 20 report. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Outperform” rating by RBC Capital Markets on Thursday, September 15. On Thursday, October 6 the stock rating was maintained by Stifel Nicolaus with “Buy”. Stifel Nicolaus maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Thursday, September 17 with “Buy” rating. The firm earned “Buy” rating on Thursday, September 17 by Cantor Fitzgerald.

AERI Company Profile

Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.

More news for Aerie Pharmaceuticals Inc (NASDAQ:AERI) were recently published by: Fool.com, which released: “Why Aerie Pharmaceuticals Is Soaring 54% Today” on September 15, 2016. Businesswire.com‘s article titled: “Aerie Pharmaceuticals to Host Investor Day on October 5, 2016” and published on September 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>